38496619|t|Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer's Disease.
38496619|a|Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer's disease (AD). Clinical trials evaluating senolytics, drugs that clear senescent cells, are underway, but lack standardized outcome measures. Our team recently published data from the first open-label trial to evaluate senolytics (dasatinib plus quercetin) in AD. After 12-weeks of intermittent treatment, we reported brain exposure to dasatinib, favorable safety and tolerability, and modest post-treatment changes in cerebrospinal fluid (CSF) inflammatory and AD biomarkers using commercially available assays. Herein, we present more comprehensive exploratory analyses of senolytic associated changes in AD relevant proteins, metabolites, lipids, and transcripts measured across blood, CSF, and urine. These analyses included mass spectrometry for precise quantification of amyloid beta (Ass) and tau in CSF; immunoassays to assess senescence associated secretory factors in plasma, CSF, and urine; mass spectrometry analysis of urinary metabolites and lipids in blood and CSF; and transcriptomic analyses relevant to chronic stress measured in peripheral blood cells. Levels of Ass and tau species remained stable. Targeted cytokine and chemokine analyses revealed treatment-associated increases in inflammatory plasma fractalkine and MMP-7 and CSF IL-6. Urinary metabolites remained unchanged. Modest treatment-associated lipid profile changes suggestive of decreased inflammation were observed both peripherally and centrally. Blood transcriptomic analysis indicated downregulation of inflammatory genes including FOS, FOSB, IL1beta, IL8, JUN, JUNB, PTGS2 . These data provide a foundation for developing standardized outcome measures across senolytic studies and indicate distinct biofluid-specific signatures that will require validation in future studies. ClinicalTrials.gov: NCT04063124.
38496619	89	108	Alzheimer's Disease	Disease	MESH:D000544
38496619	172	193	age-related disorders	Disease	MESH:D008569
38496619	204	223	Alzheimer's disease	Disease	MESH:D000544
38496619	225	227	AD	Disease	MESH:D000544
38496619	446	455	dasatinib	Chemical	MESH:D000069439
38496619	461	470	quercetin	Chemical	MESH:D011794
38496619	475	477	AD	Disease	MESH:D000544
38496619	551	560	dasatinib	Chemical	MESH:D000069439
38496619	660	672	inflammatory	Disease	MESH:D007249
38496619	677	679	AD	Disease	MESH:D000544
38496619	822	824	AD	Disease	MESH:D000544
38496619	857	863	lipids	Chemical	MESH:D008055
38496619	992	1004	amyloid beta	Gene	351
38496619	1006	1010	Ass)	Gene	445
38496619	1015	1018	tau	Gene	4137
38496619	1171	1177	lipids	Chemical	MESH:D008055
38496619	1297	1300	Ass	Gene	445
38496619	1305	1308	tau	Gene	4137
38496619	1418	1430	inflammatory	Disease	MESH:D007249
38496619	1438	1449	fractalkine	Gene	6376
38496619	1454	1459	MMP-7	Gene	4316
38496619	1468	1472	IL-6	Gene	3569
38496619	1542	1547	lipid	Chemical	MESH:D008055
38496619	1588	1600	inflammation	Disease	MESH:D007249
38496619	1706	1718	inflammatory	Disease	MESH:D007249
38496619	1735	1738	FOS	Gene	2353
38496619	1740	1744	FOSB	Gene	2354
38496619	1746	1753	IL1beta	Gene	3553
38496619	1755	1758	IL8	Gene	3576
38496619	1765	1769	JUNB	Gene	3726
38496619	1771	1776	PTGS2	Gene	5743
38496619	Association	MESH:D007249	3576
38496619	Association	MESH:D007249	6376
38496619	Association	MESH:D007249	4316
38496619	Negative_Correlation	MESH:D000069439	MESH:D000544
38496619	Association	MESH:D007249	3553
38496619	Association	MESH:D007249	5743
38496619	Association	MESH:D007249	3726
38496619	Negative_Correlation	MESH:D011794	MESH:D000544
38496619	Negative_Correlation	MESH:D008055	MESH:D007249
38496619	Association	MESH:D007249	2354
38496619	Association	MESH:D007249	2353

